Related Experiment Videos
A general extracorporeal immunoadsorption method to increase tumor-to-tissue ratio
S E Strand1, K Norrgren, M Garkavij
1Department of Radiation Physics, Lund University, Sweden.
Cancer
|February 1, 1994
Summary
Extracorporeal immunoadsorption (ECIA) using biotinylated monoclonal antibodies (MoAb) enhances radioimmunodiagnosis and radioimmunotherapy. This method significantly increased tumor-to-normal tissue ratios in preclinical models.
Area of Science:
- Biomedical engineering
- Immunology
- Oncology
Background:
- Extracorporeal immunoadsorption (ECIA) has been previously proposed for radioimmunodiagnosis and radioimmunotherapy.
- A novel, general ECIA method utilizing biotinylated monoclonal antibodies (MoAb) adsorbed onto an avidin column was developed.
Purpose of the Study:
- To develop and evaluate a new ECIA method for enhancing tumor targeting in radioimmunotherapy.
- To assess the efficacy of biotinylated MoAb-based ECIA in preclinical models of human cancers.
Main Methods:
- Athymic rats with human melanoma or lung carcinoma xenografts were injected with iodine-125-labeled biotinylated MoAb.
- Blood was processed through a plasma filter and then an avidin-agarose column for ECIA over 3 hours.
- Tumor-to-normal tissue ratios were assessed at 24 and 48 hours post-injection.
Main Results:
- The developed ECIA method successfully increased tumor-to-normal tissue ratios.
- Increases in tumor-to-normal tissue ratios ranged from four to five-fold in various tissues.
- This improvement was observed in radiosensitive and blood-rich organs.
Conclusions:
- The biotinylated MoAb-based ECIA offers a promising general method for improving radioimmunotherapy efficacy.
- This technique enhances the tumor targeting of radiolabeled antibodies, potentially leading to better therapeutic outcomes.
- Further research is warranted to translate this method into clinical applications.